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Osseous Defects to Strong Porous Scaffolds of Silicate 13-93 Bioactive Glass Doped with 




 ABSTRACT  
          The main objective of this project was to evaluate the capacity of strong porous 
silicate (13-93) bioactive glass scaffolds prepared by a robocasting technique to regenerate 
bone and stimulate angiogenesis in a rat calvarial defect model. The scaffolds were created 
with the same grid-like microstructure but in a variety of formulations: (i) as-fabricated, 
(ii) pretreated in an aqueous phosphate solution to convert the glass surface to 
hydroxyapatite, (iii) loaded with bone morphogenetic protein-2 (BMP2) (1 µg per 
scaffold), and (iv) doped with copper (0.42.0 wt. % CuO). When compared to the as-
fabricated scaffolds, the pretreated scaffolds enhanced bone regeneration at 6 weeks but 
not at 12 or 24 weeks. In comparison, the BMP2-loaded scaffolds enhanced bone 
regeneration at all three implantation times and they were almost completely infiltrated 
with lamellar bone within 12 weeks. Doping the as-fabricated scaffolds with 0.4 and 0.8 
wt. % CuO did not affect the response of preosteoblastic MC3T3-E1 cells in vitro and bone 
regeneration in vivo. In comparison, the scaffolds doped with 2.0 wt. % CuO were toxic to 
the cells in vitro and significantly inhibited bone regeneration at 6 weeks post-implantation. 
The area of new blood vessels in the new bone that infiltrated the scaffolds at 6 weeks post-
implantation was significantly enhanced by the BMP2 loading but not by CuO dopant 
concentrations of 0.4 and 0.8 wt. %. The fibrous tissue that infiltrated the scaffolds doped 
with 2.0 wt. % CuO showed a significantly higher blood vessel area than the as-fabricated 
scaffolds. Loading silicate 13-93 bioactive glass scaffolds with BMP2 significantly 
improved their capacity to regenerate bone in rat calvarial defects at 6 weeks post-
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1. PURPOSE OF THIS THESIS 
The main purpose of this research was to create and evaluate strong porous 13-93 
scaffolds of bioactive glass with grid-like architectures for potential applications in loaded 
bone repair. 
Bioactive glass and ceramics have been widely investigated for healing bone 
defects, because of their ability to enhance bone formation and to bond with surrounding 
tissue. The glass designated 13-93 (53 SiO2, 6 Na2O, 12 K2O; 5 MgO, 20 CaO and 4 P2O5, 
wt%) is a silicate-based bioactive glass with a modified 45S5 composition, which has better 
processing characteristics by viscous flow sintering than the 45S5 bioactive glass. When 
fabricated into 3D scaffolds, the 13-93 bioactive glass can be sintered to high density 
without crystallization, which leads to optimum scaffold strength. Previous research in our 
research group (Xin et al) showed that the 13-93 bioactive scaffolds with a grid-like 
microstructure, prepared by a robocasting technique, had higher mechanical properties than 
scaffolds prepared by more conventional methods, such as the polymer foam replication 
technique, which make them potential candidates for loaded bone repair. 
In this work, the grid-like 13-93 bioactive glass scaffolds were fabricated by a 
robocasting method and their ability to support bone regeneration and angiogenesis were 
evaluated in osseous defects over a long-term duration. The ability to support bone 
regeneration of the scaffolds doped with various amount of CuO were studied and 





I. Long-term bone regeneration, mineralization and angiogenesis in rat calvarial 
defects implanted with strong porous bioactive glass (13-93) scaffolds 
 
Yinan Lin1, Wei Xiao1, Xin Liu1, B. Sonny Bal2, Lynda F. Bonewald3, Mohamed N. 
Rahaman1,* 
1Department of Materials Science and Engineering Missouri University of Science and 
Technology, Rolla, MO 65409, USA  
2Department of Orthopaedic Surgery, School of Medicine, University of 
Missouri−Columbia, MO 65212, USA 
3Department of Oral and Craniofacial Sciences, School of Dentistry, University of 
Missouri– Kansas City, Kansas City, MO 64108, USA 
ABSTRACT 
There is growing interest in the use of bioactive glass scaffolds for repairing 
structural bone defects but data on the capacity of the scaffolds to regenerate bone in vivo, 
particularly over a long-term duration, are limited. In this study, bone regeneration in rat 
calvarial defects implanted with strong porous scaffolds of silicate 13-93 glass (porosity = 
47  1%) was investigated at 12 and 24 weeks post-implantation and compared with 
previous results from a similar study at 6 weeks. Three groups of implants, composed of 
as-fabricated scaffolds, scaffolds pretreated in a phosphate solution to convert a thin 
surface layer (5 µm) to hydroxyapatite (HA) and pretreated scaffolds loaded with bone 
morphogenetic protein-2 (BMP2) (1 µg/defect) were used. Bone regeneration, bioactive 
glass conversion to HA and blood vessel formation in the defects implanted with the three 
groups of scaffolds were evaluated using histology, histomorphometric analysis and 
scanning electron microscopy. When compared to the as-fabricated scaffolds, the 
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pretreated scaffolds enhanced bone regeneration at 6 weeks but not at 12 or 24 weeks. In 
comparison, the BMP2-loaded scaffolds showed a significantly better capacity to 
regenerate bone at all three implantation times and they were almost completely infiltrated 
with lamellar bone within 12 weeks. The amount of glass conversion to HA at 24 weeks 
(30−33%) was not significantly different among the three groups of scaffolds. The area 
and number of blood vessels in the new bone that infiltrated the BMP2-loaded scaffolds at 
6 and 12 weeks post-implantation were significantly greater than those for the as-fabricated 
and pretreated scaffolds. However, there was no significant difference in blood vessel area 
and number among the three groups of scaffolds at 24 weeks. The results indicate that these 
strong porous bioactive glass (13-93) scaffolds loaded with BMP2 are promising candidate 





 There is growing interest in the development of bioactive glass scaffolds for healing 
large (critical size) bone defects, particularly defects in structural bone. The attractive 
properties of bioactive glasses as a scaffold material for bone repair, such as their ability 
to stimulate osteogenesis, convert to hydroxyapatite (HA) (the mineral constituent of bone) 
and bond strongly to bone, have been well documented for 30−40 years [1−4]. However, 
most previous studies have targeted bioactive glass in the form of particles, granules or low 
strength porous scaffolds that have inadequate mechanical properties for structural bone 
repair [5]. Furthermore, while several investigations have been performed to study the 
capacity of bioactive glass scaffolds to regenerate bone in osseous defects in vivo, the 
available data covering longer-term implantation times, such as times longer than 6−12 
weeks, are limited.    
Recent studies have shown the ability to create strong porous scaffolds of silicate 
13-93 or 6P53B bioactive glass by robotic deposition techniques such as freeze extrusion 
fabrication [6] and robocasting [7, 8]. Scaffolds with a grid-like microstructure (porosity 
50%; pore width 300 µm) showed compressive strengths (~140 MPa) that were 
comparable to human cortical bone (100−150 MPa) [5]. Strong porous scaffolds of 13-93 
glass created by robocasting also showed excellent fatigue resistance in vitro under 
compressive stresses that were higher than normal physiologic stresses on the femur of 
humans [9].  
When implanted for 6 weeks in rat calvarial defects (4.6 mm in diameter), strong 
porous scaffolds of 13-93 bioactive glass were infiltrated with new bone and they 
integrated with host bone [10]. Pretreating the as-fabricated scaffolds in an aqueous 
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phosphate solution to convert a thin surface layer (5 µm) of the glass to HA prior to 
implantation significantly improved their capacity to regenerate bone. Loading the 
pretreated scaffolds with bone morphogenetic protein-2 (BMP2) (1 µg/defect) prior to 
implantation further enhanced their capacity to regenerate bone. Approximately 65% of 
the pore volume of the BMP2-loaded scaffolds was infiltrated with new bone at 6 weeks. 
More recent studies have shown promising results for the use of strong porous 13-
93 bioactive glass scaffolds in healing structural bone defects in small animals [11]. When 
implanted for 12 weeks in rat femoral segmental defects (6 mm long) using intramedullary 
pin fixation, the ends of the 13-93 scaffolds were infiltrated with new bone, resulting in 
integration. The percent new bone in the defects implanted with the 13-93 scaffolds (25%) 
was not significantly different from that in the defects implanted with autografts (38%) (n 
= 6; p < 0.05).  In another study, cylindrical scaffolds of 13-93 glass (porosity = 55−67%; 
compressive strength = 40 MPa) were prepared by selective laser sintering and evaluated 
in rat femoral segmental defects (5 mm long) [12]. The scaffolds contained drill holes in 
the sides of the cylinder that were either filled with dicalcium phosphate dihydrate (DCPD) 
used as a carrier for BMP2 (10 µg/defect) or left unfilled (control group). X-ray 
radiography and micro-computed tomography (micro-CT) showed the formation of 
bridging calluses around both groups of implants but faster healing and better callus 
formation were found for the BMP2-loaded scaffolds. 
In view of the capacity of strong porous bioactive glass (13-93) scaffolds to 
regenerate bone in rat calvarial defects at 6 weeks and to heal segmental bone defects in 
rodents at 12 weeks, this study was undertaken to evaluate longer term bone regeneration 
in osseous defects implanted with those strong porous 13-93 scaffolds. Implantation times 
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longer than 6−12 weeks are necessary for better evaluating the capacity of the scaffolds to 
heal the defect, maintain healthy bone growth and convert to HA. Two groups of scaffolds, 
pretreated for three days in an aqueous phosphate solution or loaded with BMP2, were 
implanted in rat calvarial defects for 12 and 24 weeks. The as-fabricated scaffolds (no 
pretreatment or BMP2) were used as the control group. Bone regeneration, glass 
conversion to HA and blood vessel formation in the defects implanted with the scaffolds 
were evaluated using histology, histomorphometric analysis and scanning electron 
microscopy. The results were compared with those obtained in a previous study for similar 
scaffolds implanted for 6 weeks in the same animal model [10].           
2. Materials and methods 
2.1 Preparation of scaffolds 
 Scaffolds with a grid-like microstructure were prepared using a robotic deposition 
(robocasting) method, as described in detail elsewhere [9, 10]. Briefly, the as-received 13-
93 glass (Mo-Sci Corp., Rolla, MO) was ground to form particles (1 µm), mixed with a 
20 wt% Pluronic-127 binder solution to form a paste (40 vol% glass particles) and extruded 
using a robocasting machine (RoboCAD 3.0; 3-D Inks, Stillwater, OK). After drying at 
room temperature, the scaffolds were heated in O2 at a rate of 0.5 C/min to 600 C to burn 
out the processing additives, and sintered for 1 h at 700 C (heating rate = 5 C/min) to 
densify the glass filaments. The as-fabricated scaffolds were sectioned and ground to form 
thin discs (4.6 mm in diameter  1.5 mm), washed twice with deionized water and twice 
with anhydrous ethanol, dried in air and sterilized by heating for 12 h at 250 C. For 




Twenty-eight of the as-fabricated scaffolds were reacted for 3 days in an aqueous 
phosphate solution (0.25 M K2HPO4 solution) at 60 C and a starting pH of 12.0 to convert 
a thin surface layer of the glass to HA (or amorphous calcium phosphate, ACP), as 
described previously [10]. The mass of the glass scaffolds to the volume of the K2HPO4 
solution was kept constant at 1 g per 200 ml and the solution was stirred gently each day. 
Fourteen of the pretreated scaffolds were loaded with BMP2 prior to implantation using a 
procedure described previously [10]. Briefly, a solution of BMP2 (Shenandoah 
Biotechnology Inc., PA, USA) in citric acid was prepared by dissolving 10 µg of BMP2 in 
100 µl sterile citric acid (pH = 3.0). Then 10 µl of the BMP2 solution was pipetted on to 
each bioactive glass scaffold. The BMP2 solution was completely absorbed within the 
converted surface layer of the scaffolds and there was no visible evidence for any of the 
solution flowing out of the scaffolds. After loading with BMP2, the scaffolds were kept for 
24 h in a refrigerator at 4 C to dry them prior to implantation. The release profile of the 
BMP2 from the scaffolds into a solution composed of equal volumes of fetal bovine serum 
(FBS) and phosphate-buffered saline (PBS) plus 1 vol. % penicillin was measured 
previously as a function of time in vitro [10]. 
 
2.2 Animals and surgical procedure 
All animal experimental procedures were approved by the Animal Care and Use 
Committee, Missouri University of Science and Technology, in compliance with the NIH 
Guide for Care and Use of Laboratory Animals (1985). The three groups of scaffolds 
(described as as-fabricated, pretreated and BMP2-loaded) were implanted in rat calvarial 
defects for 12 and 24 weeks. Seven scaffolds from each group were implanted for each 
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implantation time. This sample size (n = 7) was selected on the basis of the results of a 
previous study for an implantation time of 6 weeks [10] and a power analysis. The implants 
were assigned randomly to the defects, but scaffolds with and without BMP2 were not 
mixed in the same animal.  
Twenty-two male Sprague Dawley rats (3 months old; weight = 350–400 g, Harlan 
Laboratories Inc., USA) were maintained in the animal facility for 2 weeks to become 
acclimated to diet, water and housing. The rats were anesthetized with a combination of 
ketamine (72 mg/kg) and xylazine (6 mg/kg) and maintained under anesthesia with ether 
gas in oxygen. The surgical site was shaved, scrubbed with iodine and draped. Using sterile 
instruments and aseptic technique, a cranial skin incision was sharply made in an anterior 
to posterior direction along the midline. The subcutaneous tissue, musculature and 
periosteum were dissected and reflected to expose the calvarium. Bilateral full-thickness 
defects 4.6 mm in diameter were created in the central area of each parietal bone using a 
saline-cooled trephine drill. The dura mater was not disturbed.  The sites were constantly 
irrigated with sterile PBS to prevent overheating of the bone margins and to remove the 
bone debris. After the bilateral defect was implanted with the scaffold, the periosteum and 
skin were repositioned and closed using wound clips. Post-surgery, the animals were given 
a dose of ketoprofen (3 mg/kg) intramuscularly and ~200 µl penicillin subcutaneously. The 
animals were monitored daily for the condition of the surgical wound, food intake, activity 
and clinical signs of infection. After 12 and 24 weeks, the animals were sacrificed by CO2 
inhalation, and the calvarial defect sites with surrounding bone and soft tissue were 




2.3 Histologic processing 
The calvarial samples, including the surgical sites with surrounding bone and tissue, 
were fixed in 10% buffered formaldehyde for 3 days, then transferred into 70% ethanol 
and cut in half. Half of each sample was for paraffin embedding and the other half for 
methyl methacrylate embedding. The samples for paraffin embedding were de-siliconized 
by immersion for 2 h in 10% hydrofluoric acid, decalcified in 14% 
ethylenediaminetetraacetic acid (EDTA) for 4 weeks, dehydrated in a series of graded 
ethanol and embedded in paraffin using routine histological techniques. Then the 
specimens were sectioned to 5 µm using a microtome and stained with hematoxylin and 
eosin (H&E) and by the periodic acid-Schiff (PAS) technique. The un-decalcified samples 
were dehydrated in ethanol and embedded in PMMA. Sections were affixed to acrylic 
slides, ground down to 40 µm using a surface grinder (EXAKT 400CS, Norderstedt, 
Germany) and stained using the von Kossa method. Transmitted light images of the stained 
sections were taken with an Olympus BX 50 microscope connected to a CCD camera 
(DP70, Olympus, Japan). 
 
2.4 Histomorphometric analysis 
Histomorphometric analysis was carried out using optical images of the stained 
sections and the ImageJ software (National Institutes of Health, USA). One section across 
the diameter of each defect was analyzed. The percent new bone formed in the defects was 
evaluated from the H&E stained sections. The entire defect area was determined as the area 
between the two defect margins, including the entire glass scaffold and the tissue within. 
The available pore area within the scaffold was determined by subtracting the area of the 
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bioactive glass scaffold from the total defect area. The newly formed bone, fibrous tissue 
and bone marrow-like tissue within the defect area were then outlined and measured. The 
area of each tissue was expressed as a percentage of the available pore area of the scaffolds 
and total defect area. 
The von Kossa-positive area in the defects implanted with the scaffolds was 
analyzed using the von Kossa stained sections and ImageJ. One section across the diameter 
of each defect was analyzed. Images were adjusted to measure only the black-stained areas 
of the image, which yielded the black area fraction as a percentage of the total defect area. 
As mineralized bone and HA both bound the silver nitrate, in order to determine the percent 
area due to the conversion of the glass scaffold, the von Kossa-positive percentage was 
averaged for each sample and the percent new bone determined for each sample from the 
H&E stained images was subtracted. 
Quantitation of blood vessels within the defect was performed using the sections 
stained by the PAS technique, which results in purple-stained blood vessels with 
counterstaining yielding green red blood cells. Viewed at 20x field, each scaffold was 
scanned to acquire six regions of interest within the new bone and the blood vessels were 
outlined. All six areas were combined using ImageJ to determine the total blood vessel 
area, which was expressed as a percentage of the area of the selected regions. The total 
number of blood vessels in the six areas was determined and normalized to unit area (1 




2.5 Scanning electron microscopy 
Unstained sections of the implants in poly(methyl methacrylate) (PMMA) were 
coated with carbon and examined in a field-emission scanning electron microscope 
(FESEM) (S-4700; Hitachi, Tokyo, Japan) fitted with an energy-dispersive X-ray (EDS) 
spectrometer. The specimens were examined at an accelerating voltage of 15 kV and a 
working distance of 12 mm. The calcium to phosphorus (Ca/P) atomic ratio of the glass 
converted to HA, new bone and unconverted glass were measured using the as-received 
glass and a reference HA as standards. The thickness of the converted layer on the filaments 
of the scaffolds was determined as the average from three randomly selected regions. 
 
2.6 Statistical analysis 
The data are presented as a mean ± standard deviation (SD). Analysis for 
differences in new bone, mineralized tissue, and blood capillary area and number between 
groups was performed using one-way analysis of variance (ANOVA) with Tukey’s post 
hoc test. Differences were considered significant for p < 0.05. 
3. Results 
The three groups of 13-93 bioactive glass scaffolds used in this study were similar 
to those implanted previously for 6 weeks in the same animal model [10]. The as-fabricated 
scaffold had a grid-like microstructure (Fig. 1), composed of almost fully dense 13-93 glass 
filaments of diameter 330 ± 10 µm and pores of width 300 ± 10 µm in the plane of 
deposition (xy plane) and 150 ± 10 µm in the direction perpendicular to the deposition 
plane (z direction). The porosity of the scaffolds was 47 ± 1%, as measured using the 
Archimedes method. Pretreatment of the as-fabricated scaffolds in an aqueous phosphate 
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(K2HPO4) solution resulted in a porous HA surface layer on the glass filaments of thickness 
= 5  2 µm and surface area = 30  3 m2/g.     
 
3.1 Assessment of bone regeneration  
Transmitted light images of H&E stained sections of the rat calvarial defects 
implanted for 12 and 24 weeks with the as-fabricated, pretreated and BMP2-loaded 
scaffolds are shown in Fig. 2. Stained sections of defects implanted for 6 weeks with the 
three groups of scaffolds, obtained in a previous study [10], are included for comparison. 
New bone infiltrated all three groups of scaffolds, into the edges (periphery) adjacent to 
the host bone and into the pores, indicating good integration of the scaffolds with the 
surrounding calvarial bone. The amount of new bone formed in the defects was dependent 
on the implantation time and on the scaffold group. 
At 6 weeks, the amount of new bone in the as-fabricated scaffolds was limited to 
the periphery of the scaffolds and to “islands” within the pores of the scaffolds (Fig. 2a1). 
Bone regeneration was considerably greater in the defects implanted with pretreated and 
the BMP2-loaded scaffolds, with the new bone bridging the edges of the defect (Fig. 2a2, 
2a3).  The amount of new bone in the defects implanted with the pretreated scaffolds was 
not significantly different from that for the BMP2-loaded scaffolds. The as-fabricated and 
pretreated scaffolds contained a significantly higher amount of fibrous tissue than the 
BMP2-loaded scaffolds whereas the BMP2-loaded scaffolds had a significantly higher 
fraction of bone marrow-like tissue than the as-fabricated and pretreated scaffolds.  
As the implantation time increased to 12 and 24 weeks, the stained sections (Fig. 
2b1-2c3) consistently showed an increase in new bone in the defects implanted with the 
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as-fabricated and BMP2-loaded scaffolds while the amount of new bone varied over a wide 
range for the pretreated scaffolds. The new bone almost completely infiltrated the pores of 
the BMP2-loaded scaffolds within 12 weeks.  The amount of marrow-like tissue observed 
at 6 weeks in the defects implanted with the BMP2-loaded scaffolds decreased markedly 
with the increase in implantation time. Higher magnification images of the stained sections 
at 24 weeks (Fig. 2d1-2d3) showed that for all three groups of scaffolds, the new bone was 
composed of lamellar bone, similar to host bone, and that it adhered tightly to the surface 
of the scaffolds. 
Since all the scaffolds had the same microstructure, their capacity to regenerate 
bone in the defects was compared by normalizing the amount of new bone to the total pore 
space (area) of the scaffolds (Fig. 3). The amount of new bone in the as-fabricated scaffolds 
increased significantly from 45  11% at 6 weeks to 58  6% at 24 weeks. While the amount 
of new bone in the pretreated scaffolds at 6 weeks (64  9%) was significantly higher than 
that in the as-fabricated scaffolds, there was little increase with longer implantation time. 
The amount of new bone in the pretreated scaffolds at 24 weeks (67  9%) was not 
significantly higher than that in the as-fabricated scaffolds at the same implantation time. 
In comparison, the amount of new bone in the BMP2-loaded scaffolds increased 
significantly from 73  8% at 6 weeks to 95  3% at 24 weeks and was significantly greater 
than that in the as-fabricated scaffolds at all three implantation times. The amount of new 
bone in the BMP2-loaded scaffolds was also significantly greater than that in the pretreated 




3.2 Assessment of bone marrow and fibrous tissue             
 Previously, at 6 weeks post-implantation, it was found that for the as-fabricated and 
pretreated scaffolds, the pore space that was not infiltrated with new bone was filled mainly 
with fibrous (soft) tissue [10]. In comparison, the BMP2-loaded scaffolds contained a 
significantly greater amount of bone marrow-like tissue but a significantly smaller amount 
of fibrous tissue. Although the mechanism is not clear, marrow-rich bone is observed to be 
a typical outcome of BMP2-induced bone growth [13−15]. In the present study, the amount 
of bone marrow-like tissue in the BMP2-loaded scaffolds at 6 weeks post-implantation (22 
 8% of the pore space of the scaffolds) decreased significantly at 12 and 24 weeks post-
implantation (Fig. 4a). At 12 and 24 weeks, the pore space was almost completely filled 
with lamellar bone (Fig. 2c3), indicating that the marrow-like tissue had converted to 
mature bone. The amount of fibrous tissue in the as-fabricated and pretreated scaffolds 
decreased more slowly as the implantation time increased from 6 weeks to 24 weeks (Fig. 
4b).   
 
3.3 Assessment of mineralized tissue and bioactive glass conversion 
Transmitted light images of von Kossa stained sections of the rat calvarial defects 
implanted for 12 and 24 weeks with the as-fabricated, pretreated and BMP2-loaded 
scaffolds are shown in Fig. 5. Images of the defects implanted for 6 weeks with the three 
groups of scaffolds [10] are included for comparison. The von Kossa staining detects a 
combination of bone and glass converted to HA (or phosphate material). For all three 
groups of scaffolds, the total von Kossa-positive area increased as the implantation time 
increased from 6 weeks to 24 weeks. The increase was particularly noticeable for the 
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defects implanted with the BMP2-loaded scaffolds which showed a considerable amount 
of von Kossa-positive area (Fig. 5c3).  
The total von Kossa-positive area, evaluated as a fraction of the total defect area, 
was 38  9%, 56  4% and 59  5%, respectively for the as-fabricated, pretreated and 
BMP2-loaded scaffolds at 6 weeks post-implantation (Fig. 6a). At 24 weeks, the total von 
Kossa-positive area increased to 57 ± 6%, 64 ± 5% and 81 ± 4%, respectively, for the as-
fabricated, pretreated, and BMP2-loaded scaffolds. The increase in the total von Kossa-
positive area from 6 to 24 weeks was significant for each group of scaffolds but the 
magnitude of the increase was smaller for the pretreated scaffolds. 
To evaluate how much of the von Kossa-positive area was attributed to the 
converted glass alone, the percent new bone determined from the H&E stained sections (as 
a fraction of the total defect area) was subtracted from the total von Kossa-positive area. 
The percent von Kossa-positive area due to the glass conversion to HA (evaluated as a 
fraction of the total defect area) was 17  3%, 24  2% and 24  3%, respectively for the 
as-fabricated, pretreated and BMP2-loaded scaffolds at 6 weeks post-implantation (Fig. 
6b). At 24 weeks, the von Kossa-positive area due to the glass conversion increased to 29 
± 3%, 31 ± 2% and 34 ± 4%, respectively, for the as-fabricated, pretreated and BMP2-
loaded scaffolds. The increase in the von Kossa-positive area due to the glass conversion 
from 6 weeks to 24 weeks was significant for each group of scaffolds but at 24 weeks, there 
was no significant difference among the von Kossa-positive area due to the glass 




3.4. SEM evaluation of implants 
Figure 7 shows backscattered SEM images of the rat calvarial defects implanted 
with the bioactive glass scaffolds at 24 weeks. Images of the defects implanted with the 
scaffolds at 12 weeks showed similar features and they are omitted for brevity. The cracks 
in the sections and the delamination of the converted glass layer from the scaffolds are 
presumably due to mechanical stresses resulting from grinding to attain a flat surface and 
capillary stresses during the preparation (drying) of the sections for SEM analysis. The 
contrast in the grayscale images is an indication of differences in the calcium content. The 
unconverted glass, the converted surface layer and the new bone, all with higher calcium 
content, had a light gray color. In comparison, the silica-rich layer, formed in the early 
stage of the glass conversion process, was dark gray. Lacunae within the bone, fibrous 
tissue and bone marrow-like tissue were almost black. The filaments in the scaffolds 
showed a considerable amount of unconverted glass even at 24 weeks post-implantation, 
due to the well-known slow conversion of 13-93 bioactive glass [2].  
New bone appeared to bond tightly to the surface of the converted layer for all three 
groups of scaffolds at 24 weeks post-implantation. This was also found at 12 weeks for all 
three groups of scaffolds (results not included), and for the pretreated and BMP2-loaded 
scaffolds at 6 weeks [10]. New bone did not appear to bond to the as-fabricated scaffolds 
at 6 weeks. Instead, the new bone formed “islands” within the pores of the scaffolds and 
there were large gaps between the newly formed bone and the converted surface of the 
scaffold. 
The average thickness of the converted layer of the three groups of scaffolds at 24 
weeks post-implantation, determined from the SEM images (Fig. 7), was approximately 
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30, 20 and 20 µm, respectively, for the as-fabricated, pretreated, and BMP2-loaded 
scaffolds. The Ca/P atomic ratio of the converted layer, silica-rich layer and unconverted 
glass of the scaffolds and the Ca/P atomic ratio of the new bone in the defects at 12 weeks 
and 24 week post-implantation, determined using EDS analysis, are summarized in Table 
I. The Ca/P atomic ratio of the converted layer for the three groups of scaffolds did not 
show a significant change as the implantation time increased from 12 to 24 weeks. At 24 
weeks, the Ca/P atomic ratio of the converted layer was 1.62 and 1.66, respectively, 
respectively, for the as-fabricated, and BMP2-loaded scaffolds which were not 
significantly different from the value (1.67) for a stoichiometric HA. However, the Ca/P 
atomic ratio for the converted layer of the pretreated scaffolds at 24 weeks (1.54) was 
smaller than that for stoichiometric HA. 
 
3.5 Assessment of angiogenesis 
Transmitted light images of H&E and PAS stained sections showed that blood 
vessels infiltrated the defects implanted with all three groups of scaffolds. Because they 
provided more definitive detection of the micro-vessels, the PAS stained images were used 
to assess the area and number of blood vessels in the defects. Blood vessels were observed 
in the new bone, fibrous (soft) tissue and marrow-like tissue. As described earlier, the 
defects implanted for 6 weeks with the as-fabricated and pretreated scaffolds were also 
infiltrated with a considerable amount of fibrous (soft) tissue whereas the defects implanted 
with the BMP2-loaded scaffolds also contained a considerable amount of marrow-like 
tissue. A large number of blood vessels was observed in the marrow-like tissue at 6 weeks. 
Because of the difference in the amount of fibrous and marrow-like tissue in the three 
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groups of scaffolds, the blood vessel area and the number of blood vessels were evaluated 
in the new bone only.  
Figure 8 shows images of PAS stained sections of the defects implanted with the 
three groups of scaffolds at 12 weeks post-implantation. Images for implantation times of 
6 weeks and 24 weeks are omitted for brevity. At 6 weeks post-implantation, sparse 
capillary vessels were observed within the new bone in the as-fabricated scaffolds but a 
larger number of capillaries were found in the pretreated scaffolds and particularly in the 
BMP2-loaded scaffolds. At 12 weeks, along with the increase in new bone described 
earlier, there was an increase in the number of capillaries in the defects implanted with the 
BMP2-loaded scaffolds (Fig. 8c1). With an increase in the implantation time to 24 weeks, 
the morphology and color of the bone in the scaffolds were comparable to host bone, 
indicating good maturity of the infiltrated bone. The number and size of the blood vessels 
appeared to be similar to those in the host bone. 
The percent blood vessel area in the defects implanted with the three groups of 
scaffolds, determined as a fraction of the new bone area, is shown in Fig. 9a at 6, 12, and 
24 weeks post-implantation. At 6 weeks, the BMP2-loaded scaffolds had the highest 
percentage of blood vessel area within the defect (4.6  0.5%) which was significantly 
higher than the values for the as-fabricated scaffolds (2.4 ± 0.3%) and the pretreated 
scaffolds (2.7  0.3%).  The percent blood vessel area in the BMP2-loaded scaffolds 
decreased significantly to 3.1  0.5% at 12 weeks but it was still significantly higher than 
the value for the as-fabricated scaffolds (2.0  0.4%) and higher than that for the pretreated 
scaffolds (2.3 ± 0.4%). The blood vessel area in those two groups was comparable to the 
value (2%) observed in scaffolds of 13-93 glass with a fibrous microstructure implanted 
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for 12 weeks in the same animal model [16]. The percent blood vessel area at 24 weeks 
was 2.0 ± 0.2%, 2.0 ± 0.3% and 2.1 ± 0.3%, respectively, for the as-fabricated, pretreated 
and BMP2-loaded scaffolds which was approximately the same as the value in host bone 
(1.9  0.3%).  
The number of blood vessels per unit area (mm2) of the new bone in the defects 
implanted with the three groups of scaffolds was also determined (Fig. 9b). At 6 weeks, 
the number of blood vessels in the BMP2-loaded scaffolds (34  10) was significantly 
higher than in the as-fabricated scaffolds (20  4) and higher than in the pretreated scaffolds 
(29  9).  The blood vessel number in the BMP2-loaded scaffolds increased to 44  12 at 
12 weeks, whereas the vessel number in the as-fabricated scaffolds (18 ± 6) and the 
pretreated scaffolds (25 ± 6) were comparable to the values at 6 weeks. At 24 weeks, the 
blood vessel number within the new bone was 16 ± 5, 19 ± 4 and 25 ± 7, respectively, for 
the as-fabricated, pretreated and BMP2-loaded scaffolds. The differences among the 
groups were not significant. 
4. Discussion 
There is growing interest in the use of bioactive glass to heal bone defects. 
However, most previous in vivo studies have utilized bioactive glasses in the form of 
particles or weak porous 3D scaffolds and implantation times of 12 weeks or shorter. The 
significant features of the present study included the use of strong porous scaffolds that 
may have potential in healing large (critical size) defects in loaded or non-loaded bone and 
longer implantation times (12 and 24 weeks). Previously, we found that that pretreating as-
fabricated 13-93 bioactive glass scaffolds of in an aqueous phosphate solution to convert a 
thin surface layer to HA or loading the pretreated scaffolds with BMP2 significantly 
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enhanced their capacity to regenerate bone at 6 weeks. A key objective of the present study 
was to determine whether the promising bone regeneration observed at 6 weeks continued 
to longer implantation periods and to understand the processes that influence the long-term 
healing of bone defects implanted with 13-93 glass scaffolds.  
The amount of new bone in the rat calvarial defects implanted with the as-fabricated 
scaffolds increased with time and, at 24 weeks, the amount of new bone was significantly 
greater than that at 6 weeks (Fig. 3). In comparison, the significant enhancement in bone 
regeneration observed previously at 6 weeks in the defects implanted with the pretreated 
scaffolds appeared to be a short-term effect. There was little increase in the amount of new 
bone in the defects implanted with the pretreated scaffolds at 12 and 24 weeks. The 
significant difference between the as-fabricated and pretreated scaffolds to regenerate bone 
at 6 weeks was previously discussed in terms of their different surface characteristics [10]. 
Upon implantation, the surface of the pretreated scaffolds was composed of a high-surface-
area mesoporous ACP or HA material whereas the as-fabricated scaffolds was composed 
of a dense silicate glass. This difference in surface characteristics could initially influence 
the response of cells. Subsequently, the as-fabricated scaffolds converted faster to ACP or 
HA when compared to the pretreated scaffolds. After the formation of the ACP or HA 
surface layer, presumably the faster conversion of the as-fabricated scaffolds served to 
improve their capacity to regenerate bone. Thus, by 24 weeks, there was no significant 
difference in bone regeneration between the as-fabricated and pretreated scaffolds.  
The BMP2-loaded scaffolds showed the best capacity to regenerate bone. The pore 
space within the scaffolds was almost completely infiltrated with lamellar bone within 12 
weeks. Loading the 13-93 bioactive glass scaffolds with BMP2 could provide a promising 
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method for enhancing their capacity to regenerate sufficient bone within a clinically 
relevant time. The amount of BMP2 loaded into each scaffold (1 µg per defect or 60 ng per 
mm3) was well below the value (>120 ng/mm3) required for bridging 5 mm defects using 
3D poly(lactic-co-glycolic acid) scaffolds [17] and the value (250 ng/mm3) observed to 
cause adverse biological effects in the same animal model [18]. In the present study, no 
adverse biological effects were observed in the H&E stained sections of the defects 
implanted with the three groups of scaffolds for the three implantation times used. 
 The defect size (4.6 mm) used in the present study is not a critical size defect in the 
rat calvarial model. However, a defect size of 5 mm in this animal model has been used 
often to evaluate the response of biomaterials in osseous defects. The defect size in the 
present study was based on the diameter of a commercially available trephine drill and the 
use of bilateral defects (one defect in the central area of each parietal bone of the calvaria). 
For an unfilled defect of that size, our previous study showed that only a thin layer of new 
bone was formed at the defect margin at 12 weeks and most of the defect was filled with 
compressed fibrous connective tissue [19]. The thin layer of bone formed after 12 weeks 
failed to bridge the defect at after 24 weeks. Thus the healing of the defects observed in the 
present study can be attributed mainly to the capacity of the BMP2-loaded scaffolds to 
stimulate osteogenesis.     
The release profile of BMP2 from the scaffolds into a medium composed of fetal 
bovine serum and phosphate-buffered saline, measured previously [10], showed that 10% 
of the BMP2 loaded into the scaffolds was released over the first 3−4 days and that the 
release of BMP2 almost ceased thereafter. Despite this limited short-term release of BMP2 
observed in vitro, the results of the present study showed a significant capacity of the 
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BMP2-loaded scaffolds to enhance bone regeneration for up to 24 weeks in vivo. A thin 
surface layer of the scaffolds was converted to a high-surface-area hydroxyapatite (30  3 
m2/g) that served as a substrate for the BMP2. Because of the high affinity of BMP2 for 
HA, its release rate from HA in vitro is often low. The adsorbed BMP2 is reported to be 
strongly immobilized on the surface of the HA by electrostatic and other interactions, such 
as hydrogen bonding [20]. This strong interaction makes it difficult for the BMP2 to be 
displaced from the HA surface by competitive adsorption from other proteins [21]. 
However, a greater release of BMP2 from the scaffolds can be expected in vivo because of 
a higher degradation rate of the HA surface layer due to cell-mediated degradation in 
addition to dissolution-mediated degradation [22, 23] and the higher solubility of proteins 
in vivo. Presumably the BMP2 release in vivo was above the threshold required to stimulate 
bone regeneration over a period that was much longer than the release time observed in 
vitro. 
 An attractive property of bioactive glasses is their ability to convert to HA which 
leads to a strong bond with bone. The rate of conversion to HA depends primarily on the 
bioactive glass composition, the medium (in vitro versus in vivo) and the architecture of 
the glass (porosity, pore size and pore interconnectivity) [16, 19, 24−27]. As the bioactive 
glass scaffold converts to HA, its strength decreases [9, 19]. Consequently, the application 
of bioactive glass scaffolds in structural or loaded bone repair depends not only on the 
strength of the as-fabricated scaffold but also on the relative rates of conversion 
(degradation in strength) and new bone infiltration (enhancement in strength). A 
requirement for structural bone repair is to avoid rapid degradation in the strength prior to 
sufficient new bone infiltration. The slow conversion rate of silicate 13-93 bioactive glass 
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scaffolds to HA is an advantage for the retention of strength. The amount of glass 
conversion at 24 weeks, determined by subtracting the percent new bone in the defects 
from the total von Kossa-positive area was 30−33% for the three groups which showed 
that the pretreatment or BMP2 loading had little long-term effect on conversion of the 
scaffolds in the defects. If required, more rapid conversion of the 13-93 scaffolds to HA 
can be achieved by reducing the diameter of the glass filaments in the grid-like architecture 
(Fig. 1). 
Angiogenesis is essential for bone formation and growth, and it plays a critical role 
in bone defect repair [28]. Blood vessels provide a means for tissues to receive oxygen and 
various nutrients. The relationship between angiogenesis and osteogenesis is well 
recognized [29]. The vasculature penetrates into the bioactive glass scaffold and enables 
numerous cells and tissues to receive nourishment. The enhancement of angiogenesis 
increases bone regeneration [30]. In the present study, the area and number blood vessels 
in the new bone that infiltrated the BMP2-loaded scaffolds at 6 and 12 weeks were 
significantly greater than those for the as-fabricated or pretreated scaffolds, showing the 
capacity of the BMP2-loaded scaffolds to enhance angiogenesis. The blood vessel area and 
number showed a decreasing trend with time and became comparable to the values in host 
bone within 24 weeks. 
Together, the results of the present study showed that loading the 13-93 bioactive 
glass scaffolds with a moderate amount of BMP2 (1 g per defect) resulted in their ability 
to stimulate osteogenesis and angiogenesis in a rat calvarial defect model, particularly at 
shorter implantation times (<12 weeks). Extensive data have shown that BMPs, 
particularly BMP2, can initiate the complete cascade of bone formation, including the 
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migration of mesenchymal stem cells and their differentiation into pre-osteoblasts and then 
into osteoblasts [31, 32]. While several growth factors can play a role in angiogenesis, 
vascular endothelial growth factor (VEGF) is considered to be a key regulator of 
angiogenesis during bone regeneration [33]. Studies have shown that BMP-induced 
differentiation of pre-osteoblast-like cells can enhance the production of VEGF by the 
resulting osteoblasts [34, 35]. The simultaneous delivery or expression of BMP and VEGF 
has been shown to result in enhanced bone formation in vivo [3638]. In the present study, 
presumably enhanced production of VEGF by the osteoblasts stimulated angiogenesis and 
this, coupled with the continuous release of BMP2 from the scaffolds, served to enhance 
new bone formation in the defects.  
5. Conclusions 
Bone regeneration in rat calvarial defects implanted with strong porous bioactive 
glass (13-93) scaffolds was studied at implantation times of 12 and 24 weeks and compared 
with a similar study at 6 weeks. Bone regeneration in the defects implanted with the as-
fabricated scaffolds increased significantly with increase in the implantation time from 6 
to 24 weeks. Pretreating the scaffolds to convert a thin surface layer to hydroxyapatite 
enhanced bone regeneration at 6 weeks but not at 12 or 24 weeks. Scaffolds loaded with 
BMP2 (1 µg/defect) significantly enhanced bone regeneration at all three implantation 
times. The pore space of the BMP2-loaded scaffolds was almost completely infiltrated with 
lamellar bone within 12 weeks. The pretreatment or BMP2 loading did not affect the 
amount of bioactive glass converted to hydroxyapatite at 24 weeks (30%). While blood 
vessels were present in the new bone that infiltrated all three groups of scaffolds, the 
BMP2-loaded scaffolds had a significantly higher number of blood vessels and blood 
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vessel area at 6 and 12 weeks post-implantation. Strong porous bioactive glass (13-93) 
scaffolds loaded with clinically acceptable levels of BMP2 could provide promising 
implants for healing structural (loaded) bone defects within a clinically relevant time.  
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Fig. 1. (a) Optical image of 13-93 bioactive glass scaffold prepared by robocasting for 
implantation in rat calvarial defects [10]. (b) Higher-magnification SEM image of the 
scaffold showing dense glass filaments and porous grid-like architecture in the plane of 
deposition (xy plane). Inset: SEM image in z direction. The scaffolds had a porosity of 47 






Fig. 2. Transmitted light images of H&E-stained sections of rat calvarial defects implanted 
for 6 weeks (a1−a3), 12 weeks (b1−b3) and 24 weeks (c1−c3) with the three groups of 
bioactive glass scaffolds: as-fabricated (a1−c1), pretreated (a2−c2) and BMP2-loaded 
(a3−c3). Higher magnification images of the boxed areas in (c1−c3) are shown in (d1−d3).  
N = new bone; O = host bone; * = bony island; G = bioactive glass; arrowheads indicate 






Fig. 3. Percent new bone in rat calvarial defects implanted with the three groups of 
scaffolds for 6, 12 and 24 weeks. The amount of new bone is shown as a percent of the 
available pore space (area) of the scaffolds. (*significant difference within each group; 
**significant difference when compared to as-fabricated scaffold at the same implantation 






Fig. 4. Percent bone marrow-like tissue (a) and fibrous tissue (b) in rate calvarial defects 
implanted with the three groups of scaffolds for 6, 12 and 24 weeks. (*significant 
difference within each group; **significant difference when compared to as-fabricated 






Fig. 5. Transmitted light images of von Kossa stained sections of rat calvarial defects 
implanted for 6 weeks (a1−a3), 12 weeks (b1−b3) and 24 weeks (c1−c3) with the three 
groups of bioactive glass scaffolds: as-fabricated (a1−c1), pretreated (a2−c2) and BMP2-
loaded (a3−c3).   N = new bone; O = host bone; G = bioactive glass; arrowheads indicate 






Fig. 6. Percent total von Kossa positive (vK+) area (a) and vK+ area due to the bioactive 
glass conversion (b), determined as a fraction of the total defect area, for rat calvarial 
defects implanted with the three groups of scaffolds at 6, 12 and 24 weeks post-
implantation. (*significant difference within each group; **significant difference when 






Fig. 7. Backscattered SEM images of rat calvarial defects implanted with bioactive glass 
scaffolds at 24 weeks post-implantation: (a1, a2) as-fabricated scaffolds; (b1, b2) pretreated 
scaffolds; (c1, c2) BMP2-loaded. N = new bone; G = bioactive glass. The approximate 






Fig. 8. Transmitted light images of PAS stained sections of rat calvarial defects implanted 
with the three groups of bioactive glass scaffolds at 12 weeks post-implantation: (a1, a2) 
as-fabricated scaffolds; (b1, b2) pretreated scaffolds; (c1, c2) BMP2-loaded scaffolds. 






Fig. 9. (a) Percent blood vessel area and (b) number of blood vessels per unit area (mm2) 
of new bone in rat calvarial defects implanted with the three groups of scaffolds at 6, 12 
and 24 weeks post-implantation. (*significant difference within each group; **significant 




Table I. Calcium to phosphorus (Ca/P) atomic ratio for new bone, converted glass layer, 
silica-rich layer and unconverted glass in rat calvarial defects implanted with as-fabricated, 















12 1.72 ± 0.06 1.59 ± 0.04 2.6 ± 0.2 5.8 ± 0.3 
24 1.68 ± 0.08 1.62 ± 0.06 2.3 ± 0.1 5.4 ± 0.3 
Pretreated 
12 1.73 ± 0.06 1.50 ± 0.05 2.3 ± 0.2 5.6 ± 0.4 
24 1.70 ± 0.05 1.54 ± 0.07 2.2 ± 0.3 5.6 ± 0.2 
 
BMP2-loaded 
12 1.71 ± 0.06 1.61 ± 0.05 2.5 ± 0.3 5.8 ± 0.3 
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ABSTRACT 
Copper ions are known to stimulate angiogenesis, a process that is essential for 
tissue regeneration, but high Cu ion concentration is toxic to cells and tissues. In the present 
study, porous scaffolds of silicate 13-93 bioactive glass doped with varying concentrations 
of Cu (02.0 wt. % CuO) were created by robotic deposition and their effect on the 
response of mouse preosteoblastic MC3T3-E1 cells in vitro and bone regeneration and 
angiogenesis in rat calvarial defects in vivo was investigated. When immersed in simulated 
body fluid (SBF) in vitro, the Cu-doped scaffolds released Cu ions into the medium in a 
dose-dependent manner and converted partially to hydroxyapatite. The number and 
alkaline phosphatase activity of MC3T3-E1 cells cultured on the scaffolds were not 
affected by CuO concentrations of 0.4 and 0.8 wt. % in the glass but they were significantly 
reduced by 2.0 wt. % CuO. Bone infiltration of the 13-93 scaffolds implanted for 6 weeks 
in rat calvarial defects (46 ± 8 % of the total pore area or volume) was not significantly 
affected by 0.4 or 0.8 wt. % CuO in the glass. In comparison, bone formation (0.8 ± 0.7 %) 
was significantly inhibited while fibrous (soft) tissue was significantly enhanced in the 
scaffolds doped with 2.0 wt. % CuO. The area of new blood vessels in the fibrous tissue 
that infiltrated the scaffolds increased with CuO content of the glass and was significantly 
higher for the scaffolds doped with 2.0 wt. % CuO. Loading the scaffolds with bone 
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morphogenetic protein-2 (BMP2) (1 µg/defect) significantly enhanced bone infiltration 
and reduced fibrous tissue in the scaffolds. Collectively, these results indicate that doping 
13-93 bioactive glass scaffolds with up to 0.8 wt. % CuO had no significant benefit on 
MC3T3-E1 cell proliferation in vitro and bone regeneration in vivo whereas a CuO dopant 
concentration of 2.0 wt. % was toxic to cells and detrimental to bone regeneration. 
1. Introduction 
There is a clinical need for synthetic bioactive implants that can reliably repair large 
(critical size) bone defects, particularly segmental defects in load-bearing bones. Whereas 
contained bone defects are repairable with commercially-available, osteoconductive and 
osteoinductive filler materials [1, 2], the repair of large defects in structural bone is a 
challenging clinical problem. The available treatments such as bone allografts, autografts 
and porous metals are limited by costs, availability, durability, infection risk, donor site 
morbidity, and uncertain healing.  
Ideally, synthetic implants for bone regeneration should have a combination of 
desirable properties [3]. They should be biocompatible, osteoconductive and 
osteoinductive, and they should have a porous three-dimensional (3D) architecture with 
interconnected porosity for tissue ingrowth and formation of capillaries [4]. Synthetic 
implants should also be bioactive and they should degrade or resorb at a controllable rate, 
comparable to the rate of bone regeneration. While the target mechanical properties are not 
well established, an often-used guideline is that the mechanical properties of the scaffold 
should match those of the host bone. Synthetic biomaterials for bone repair should also 
have the ability to be formed into anatomically relevant shapes by commercial methods 
and to be sterilized according to international standards for clinical use.  
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Synthetic biomaterials generally lack the osteoinductivity and osteogenicity of 
autogenous bone grafts, functioning mainly as osteoconductive implants. Consequently, 
the performance of synthetic biomaterials in vivo is inferior to that of autogeneous bone 
grafts (the gold standard for bone repair). The use of synthetic biomaterials by themselves 
commonly fails to produce clinically significant bone formation in a clinically relevant 
time [5, 6]. In practice, the addition of osteogenic growth factors to synthetic biomaterials 
is often needed to achieve reliable reconstruction of bone [7, 8]. Bone morphogenetic 
proteins (BMPs) such as BMP2, delivered typically by osteoconductive biomaterials, can 
induce robust bone formation and they have been used successfully in bone repair [79]. 
However, BMPs are commonly effective only when used in supra-physiological doses and 
this has resulted in heightened concerns about adverse biological effects in vivo [10, 11].   
Angiogenesis is essential for bone formation and growth and plays a critical role in 
bone defect repair [12]. The relationship between angiogenesis and osteogenesis has been 
well established [13]. The vasculature transports oxygen, nutrients, soluble factors and 
numerous cell types to all tissues in the body. The enhancement of angiogenesis should 
increase osteogenesis [14]. While a variety of approaches have been developed to enhance 
angiogenesis by synthetic implants, a commonly-used approach is the incorporation of 
angiogenic factors such as vascular endothelial growth factor (VEGF), basic fibroblast 
growth factor (bFGF) and platelet-derived growth factor [15, 16]. However, the use of 
growth factors typically suffers from disadvantages such as high cost, potential adverse 
biological effects in vivo when used in supra-physiological doses and loss of bioactivity 
[10, 11, 17, 18]. 
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Inorganic angiogenic factors such as Cu2
＋
 ions are of interest because of their low 
cost, high stability and potentially better clinical safety when compared to growth factors 
[1921]. Copper ions have been reported to enhance angiogenesis by stabilizing the 
expression of hypoxia-inducible factor (HIF-1α), thus mimicking hypoxia, which plays a 
critical role in the recruitment and differentiation of cells and in blood vessel formation 
[19, 20]. The release of Cu2+ ions has been shown to stimulate the expression of 
proangiogenic factors such as VEGF and transforming growth factor-β (TGF-β) in wounds 
created in diabetic mice [22, 23]. Subcutaneous implantation of Cu-containing borate 
bioactive glass microfibers in rats significantly enhanced the growth of capillaries and 
small blood vessels when compared to silicate 45S5 bioactive glass microfibers and sham 
implant controls [24]. The ionic dissolution product of Cu-doped borate bioactive glass 
microfibers has been shown to stimulate the expression of angiogenic genes of fibroblasts 
in vitro and angiogenesis in full thickness skin wounds in rodents in vivo [25].  Scaffolds 
of a Cu-doped borosilicate bioactive glass have been shown to enhance blood vessel 
formation and bone regeneration in rat calvarial defects in vivo [26]. 
The attractive properties of bioactive glasses as a scaffold material for bone repair 
have been well described and reviewed in the literature [27, 28]. Bioactive glasses can be 
doped with inorganic ions such as Cu, Zn, Sr and Fe that have been reported to stimulate 
angiogenesis and/or osteogenesis. As the glass degrades, those ions are released at a 
therapeutically appropriate concentration. As described above, the release of Cu and other 
ions from borate and borosilicate bioactive glasses has been reported to enhance 
angiogenesis in soft tissue repair and both angiogenesis and osteogenesis in rat calvarial 
defects in vivo. However, borate-based bioactive glasses are not currently approved by the 
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US Food and Drug Administration for in vivo use in humans and some borate-based glasses 
may degrade too rapidly for applications in structural bone repair. While silicate bioactive 
glasses such as 45S5 and 13-93 have been used in bone repair applications for several years 
[28], the effects of Cu doping on their ability to stimulate angiogenesis and osteogenesis 
has received little attention. 
The objective of the present study was to create porous scaffolds of silicate 13-93 
glass doped with varying concentrations of Cu (02.0 wt. % CuO) and evaluate the ability 
of the Cu dopant to stimulate the proliferation and function of pre-osteoblastic MC3T3-E1 
cells in vitro and bone regeneration and angiogenesis in osseous defects in vivo.  The effect 
of the Cu doping on bone regeneration and angiogenesis was compared with an alternative 
approach based on loading the scaffolds with BMP2.  
2. Materials and methods 
2.1 Preparation of scaffolds 
Scaffolds of the parent 13-93 glass (composition 53SiO2, 6Na2O, 12K2O, 5MgO, 
20CaO, 4P2O5; wt. %) and the 13-93 glass doped with 0.4, 0.8 and 2.0 wt. % CuO were 
created with a grid-like microstructure using a robotic deposition (robocasting) method 
described in detail elsewhere [29]. Briefly, each glass was prepared by melting the requisite 
amount of chemicals (Cu(NO3)2·21 2⁄ H2O, SiO2, Na2O, CaO, MgO, K2O, P2O5) for 30 min 
in a platinum crucible at 1350 C and quenching the molten glass between cold stainless 
steel plates. The crushed glass was grounded in a hardened steel container (8500 
Shatterbox®, Spex SamplePrep LLC., Metuchen, NJ) to give particles of size <50 µm. Then 
the particles were milled for 2 h in an attrition mill (Union Process, Inc., Akron, OH) using 
water as the liquid medium and ZrO2 grinding media (3 mm in diameter) to give particles 
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of size 1.0 ± 0.5 µm, as measured by a laser diffraction particle size analyzer (Model LS, 
Beckman Coulter Inc., CA). The glass was mixed with a 20 wt. % Pluronic-127 binder 
solution to form a paste (40 vol. % glass particles) and extruded using a robocasting 
machine (RoboCAD 4.1; 3-D Inks, Stillwater, OK). After drying at room temperature, the 
scaffolds were heated in O2 at a rate of 0.5 C/min to burn out the processing additives, and 
sintered for 1 h at 700 C (heating rate = 5 C/min) to densify the glass filaments. The as-
fabricated scaffolds were sectioned and grounded to form thin discs (4.6 mm in diameter 
 1.5 mm), washed twice with deionized water and twice with anhydrous ethanol, dried in 
air and sterilized by heating for 12 h at 250 C.  
Thirty-two as-fabricated scaffolds were loaded with BMP2 at a concentration of 1 
µg per scaffold prior to implantation in vivo using a method described previously [30]. 
Briefly, the scaffolds were reacted for 3 days in an aqueous phosphate solution (0.25 M 
K2HPO4 solution) at 60 C and a starting pH of 12.0 to convert a thin surface layer (5 µm) 
of the glass to HA (or amorphous calcium phosphate, ACP). The mass of the glass scaffolds 
to the volume of the K2HPO4 solution was kept constant at 1 g per 200 ml and the solution 
was stirred gently each day. The reacted scaffolds were removed from the solution, washed 
twice with deionized water, and twice with anhydrous ethanol to displace residual water 
from the scaffolds. Then the scaffolds were dried for at least 24 h at room temperature and 
stored in desiccator.  
In the BMP2 loading process, a solution of BMP2 (Shenandoah Biotechnology Inc., 
PA) in citric acid was prepared by dissolving 10 µg of BMP2 in 100 µl sterile citric acid 
(pH = 3.0). Then 10 µl of the BMP2 solution was pipetted on to each scaffold (4.6 mm in 
diameter × 1.5 mm). The amount of BMP2 loaded into the scaffolds was equivalent to 1 
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µg per bone defect (or per scaffold) in the animal model. The BMP2 solution was totally 
incorporated in the converted surface layer of the scaffolds and there was no visible 
evidence for any of the solution flowing out of the scaffolds. After loading with BMP2, the 
scaffolds were kept for 24 h in a refrigerator at 4 C to dry them prior to implantation.   
 
2.2 Degradation and conversion of scaffolds in simulated body fluid (SBF) in vitro 
The degradation of the bioactive glass scaffolds (4.6 mm in diameter  1.5 mm) 
and their conversion to HA were studied as a function of immersion time in SBF [31] with 
a starting pH of 7.4. The concentration of Cu ions released from the scaffolds into the SBF 
during the degradation and conversion process was determined using inductively-coupled 
plasma optical emission spectrometry (ICP-OES). The weight loss of the scaffolds was 
measured as a function of time and used as a measure of the conversion of the glass to HA 
while the pH of the medium was measured using a pH meter, as described previously [32, 
33]. A ratio of 1 g of scaffold to 100 ml of SBF was used in all of the conversion 
experiments. The weight loss and pH measurements at each time point were measured in 
triplicate and the data were expressed as a mean ± standard deviation (SD). The formation 
of HA on the surface of the scaffolds was characterized using scanning electron 
microscopy, SEM (S-4700; Hitachi, Tokyo, Japan) and Raman spectroscopy (Horiba-Jobin 
Yvon, Inc., Edison, NJ). The samples were coated with Au/Pd and examined in the SEM 
at an accelerating voltage of 15 kV and a working distance of 12 mm. The Raman spectra 




2.3 Cell culture  
This in vitro study was performed to evaluate the effect of the Cu ions released 
from the scaffolds on the ability of the scaffolds to support the growth and differentiation 
of an established osteogenic cell line. The established MC3T3-E1 line of mouse pre-
osteoblastic cells was obtained from ATCC (CRL-2593) and cultured in minimum essential 
medium (alpha modification; α-MEM) supplemented with 10% fetal bovine serum plus 5 
µg ml-1 gentamicin. This cell line has been used extensively in previous in vitro 
investigations to test the response of biomaterials to cells. Prior to cell seeding, the 
sterilized scaffolds were subjected to a 1 h preconditioning soak in normal medium. The 
conditioned scaffolds were blotted dry, rinsed twice with phosphate-buffered saline (PBS), 
placed on a 6 cm diameter Teflon disk, and seeded with 5 × 104 MC3T3-E1 cells suspended 
in 35 µl of complete medium, as in our previous studies using this cell line and bioactive 
glass scaffolds [34]. Following a 4 h incubation to permit cell attachment, the scaffolds 
with attached cells were transferred to a 24-well untreated plate with 2 ml of complete 
medium per well. The control group consisted of the same number of cells seeded in wells 
containing 2 ml of complete medium. All cell cultures were maintained at 37 C in a 
humidified atmosphere of 5% CO2, with the media changed every 2 days.  
 
2.3.1 Cell morphology 
SEM (Hitachi S-4700) was used to examine the morphology of cells adhered to the 
scaffolds. At culture intervals of 2, 7 and 14 days, the glass scaffolds with attached cells 
were removed, washed twice with warm PBS and soaked overnight in 2.5% glutaraldehyde 
in PBS. The fixed samples were washed 3 times with PBS, post-fixed with 1% osmium 
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tetroxide in PBS for 1 h, washed 3 times with PBS, dehydrated with a graded ethanol series 
and soaked for 10 min in hexamethyldisilazane (HMDS). Then the samples were dried in 
air to allow the liquid to fully evaporate, sputter-coated with Au/Pd and examined in the 
SEM at an accelerating voltage of 15 kV and a working distance of 12 mm. 
 
2.3.2 Cell viability and proliferation 
The proliferation of MC3T3-E1 cells on the scaffolds was assessed using a cell 
viability assay (Cell Counting Kit-8 (CCK-8), Dojindo Molecular Technologies, Inc., 
Japan). Briefly, MC3T3-E1 cells were cultured on the scaffolds (n = 3) using the procedure 
described above at an initial density of 5 × 103 cells per scaffold (as recommended in the 
CCK-8 assay protocol) for 2, 4, 7 and 14 days. An unseeded scaffold was used as a control. 
Subsequently, 360 µl of serum-free α-MEM and 40 µl of CCK-8 solution were added to 
each well at each time point and the system was incubated for 3 h at 37 C in a humidified 
5% CO2 atmosphere. The formazan solution in the wells was extracted by pipetting gently 
several times and aliquots (100 µl) from each well were transferred to a fresh 96-well plate. 
The absorbance of the colored formazan solution in the samples was measured using a 
microplate reader (FLUOstar Omega; BMG Labtech, Offenburg, Germany) at 450 nm. The 
results were expressed as the optical density of the aliquots minus the absorbance of the 
blank wells. 
The effect of Cu ions released from the glass scaffolds on the viability of the 
MC3T3-E1 cells was evaluated using a live cell/dead cell assay. After culturing for 2, 7, 
14 and 21 days using the procedure described above, the scaffolds were rinsed with warm 
PBS and incubated for an additional 30 min in 10 ml sterile tissue culture-grade Dulbecco’s 
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PBS (DPBS) containing 2 µM calcein AM and 4 µM ethidium homodimer-1 (EthD-1; Life 
Technologies, Grand Island, NY). Images were collected under an epifluorescent 
microscope fitted with appropriate exciter and emitter filters to detect live (green 
fluorescent) and dead (red fluorescent) cells. 
 
2.3.3 Alkaline phosphatase (ALP) activity 
After culturing for 3, 7 and 14 days, the grid-like scaffolds with attached cells were 
removed, rinsed twice with PBS, subjected to three freeze/thaw cycles at 80 C/37 C, 
lysed in 500 µl of 0.5% Triton X-100 in PBS, and homogenized by sonication for 30 s on 
ice. The lysed cell suspension was spun at 3000 rpm for 10 min in a refrigerated 
microcentrifuge to sediment particulate debris. The ALP activity was assayed using a 
colorimetric p-NPP method. The absorbance was measured on a microplate reader 
(FLUOstar Omega; BMG Labtech, Offenburg, Germany) at 405 nm after 30 min 
incubation at 37 C. ALP specific activity levels were quantified with a standard curve and 
normalized to the amount of total cellular dsDNA from the same sample. The dsDNA 
content was determined using a Pico Green assay (Molecular Probes). A 50 µl volume of 
working reagent was added to the 50 µl cell lysate of the sample and the sample was read 
at 485/528 nm (excitation/emission) on a fluorescence spectrophotometer (FLUOstar 
Omega, BMG Labtech, Offenburg, Germany). The amount of dsDNA was calculated by 
comparing the standard curves of the known dsDNA sample according to the protocol 




2.4. Evaluation of scaffolds in rat calvarial defects in vivo 
All animal experimental procedures were approved by the Animal Care and Use 
Committee, Missouri University of Science and Technology, in compliance with the NIH 
Guide for Care and Use of Laboratory Animals (1985). Eight groups of scaffolds, 
composed of the parent 13-93 glass and the 13-93 glass doped with 0.4, 0.8 and 2.0 wt. % 
CuO without BMP2 plus these four groups of scaffolds loaded with BMP2 (1 µg per 
scaffold or defect), were implanted in bilateral defects in rat calvaria for 6 weeks. This 
animal model was used because it is a standard assay for evaluating the response of 
biomaterials in osseous defects. Eight scaffolds from each group were implanted randomly 
in the defects but scaffolds with and without BMP2 were not mixed in the same animal. 
The sample size (number of replicates per group, n = 8) was based on the results of a 
previous study for 13-93 glass scaffolds implanted for the same time in the same animal 
model [30] and a power analysis.  
 
2.4.1 Animals and surgical procedure 
Thirty-two male Sprague Dawley rats (3 months old; weight = 350–400 g, Harlan 
Laboratories Inc., USA) were maintained in the animal facility for 2 weeks to become 
acclimated to diet, water and housing. The rats were anesthetized with a combination of 
ketamine (72 mg/kg) and xylazine (6 mg/kg) and maintained under anesthesia with ether 
gas in oxygen. The surgical site was shaved, scrubbed with iodine and draped. Using sterile 
instruments and aseptic technique, a cranial skin incision was sharply made in an anterior 
to posterior direction along the midline. The subcutaneous tissue, musculature and 
periosteum were dissected and reflected to expose the calvarium. Bilateral full-thickness 
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defects 4.6 mm in diameter were created in the central area of each parietal bone using a 
saline-cooled trephine drill. The dura mater was not disturbed.  The sites were constantly 
irrigated with sterile PBS to prevent overheating of the bone margins and to remove the 
bone debris. After the bilateral defect was implanted with the scaffold, the periosteum and 
skin were repositioned and closed using wound clips. The animals were given a dose of 
ketoprofen (3 mg/kg) intramuscularly and ~200 µl penicillin subcutaneously post-surgery, 
and monitored daily for the condition of the surgical wound, food intake, activity and 
clinical signs of infection. After 6 weeks, the animals were sacrificed by CO2 inhalation, 
and the calvarial defect sites with surrounding bone and soft tissue were harvested for 
subsequent evaluation. 
 
2.4.2 Histologic processing 
The calvarial samples, including the surgical sites with surrounding bone and tissue, 
were fixed in 10% buffered formaldehyde for 3 days, then transferred into 70% ethanol 
and cut in half. Half of each sample was for paraffin embedding and the other half for 
methyl methacrylate embedding. The samples for paraffin embedding were de-siliconized 
by immersion for 2 h in 10% hydrofluoric acid, decalcified in 14% 
ethylenediaminetetraacetic acid (EDTA) for 4 weeks, dehydrated in a series of graded 
ethanol and embedded in paraffin using routine histological techniques. Then the 
specimens were sectioned to 5 µm using a microtome and stained with hematoxylin and 
eosin (H&E) and periodic acid-Schiff (PAS) staining technique. The un-decalcified 
samples were dehydrated in ethanol and embedded in PMMA. Sections were affixed to 
acrylic slides, ground down to 40 µm using a surface grinder (EXAKT 400CS, Norderstedt, 
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Germany) and stained using the von Kossa method. Transmitted light images of the stained 
sections were taken with an Olympus BX 50 microscope connected to a CCD camera 
(DP70, Olympus, Japan). 
 
2.4.3 Histomorphometric analysis 
Histomorphometric analysis was carried out using optical images of the stained 
sections and the ImageJ software (National Institutes of Health, USA). One section across 
the diameter of each defect was analyzed. The percent new bone formed in the defects was 
evaluated from the H&E stained sections. The entire defect area was determined as the area 
between the two defect margins, including the entire glass scaffold and the tissue within. 
The available pore area within the scaffold was determined by subtracting the area of the 
bioactive glass scaffold from the total defect area. The newly formed bone, fibrous tissue 
and bone marrow-like tissue within the defect area were then outlined and measured. The 
area of each tissue was expressed as a percentage of the available pore area of the scaffolds 
and total defect area. 
The von Kossa-positive area in the defects implanted with the scaffolds was 
analyzed using the von Kossa stained sections and ImageJ. One section across the diameter 
of each defect was analyzed. Images were adjusted to measure only the black-stained areas 
of the image, which yielded the black area as a percentage of the total defect area. As 
mineralized bone and hydroxyapatite due to the glass conversion both bound the silver 
nitrate, in order to determine the percent area due to the conversion of the glass scaffold, 
the von Kossa-positive percentage was averaged for each sample and the percent new bone 
determined for each sample from the H&E stained images was subtracted. 
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Quantitation of blood vessels within the defect was performed using sections 
stained by the PAS technique, which results in purple-stained blood vessels with 
counterstaining yielding green-colored red blood cells. Viewed at 20x, each scaffold was 
scanned to acquire six regions of interest each within the fibrous tissue and new bone, and 
the blood vessels were outlined. All six areas were combined using ImageJ to determine 
the total blood vessel area, which was expressed as a percentage of the total area of the 
respective tissue (fibrous tissue or new bone).  
 
2.5 Statistical analysis 
All cell culture experiments (4 samples in each group) were run in triplicate. The 
data are presented as mean ± SD. Analysis for differences between groups was performed 
using one-way ANOVA with Tukey’s post hoc test. Differences were considered 
significant for p < 0.05. Statistical calculations were performed using the software package 
SigmaStat for Windows Version 2.03. 
3. Results 
3.1 Characteristics of as-fabricated scaffolds 
 The as-fabricated Cu-doped scaffolds (Fig. 1a) appeared blue, an indication that 
the Cu in the glass was present as Cu2+ ions, and the intensity of the blue color increased 
with the Cu concentration in the glass. The Cu dopant did not have any observable effect 
on the microstructure of the scaffolds, presumably because of the low Cu concentration in 
the glass and the use of a robocasting method to create the scaffolds which allowed precise 
control of the scaffold architecture. The scaffolds had a grid-like microstructure, composed 
of dense glass filaments (330 µm in diameter) and pores of size 300 µm in the plane of 
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deposition (xy plane) (Fig.1b) and 150 µm in the direction at right angles to the plane of 
deposition (z direction). 
 
3.2 Degradation and conversion of scaffolds to hydroxyapatite in SBF 
Immersion of the scaffolds in SBF resulted in the formation of a needle-like product 
on the surface of the glass filaments (Fig. 1c) which is typical of hydroxyapatite (HA) 
formed on the surface of bioactive glasses reacted in an aqueous phosphate solution [33]. 
Raman spectroscopy of the reacted scaffolds showed that the major resonance line 
corresponded to HA (Fig. S1).  
Immersion of the scaffolds in SBF also resulted in a weight loss of the scaffolds 
(Fig. 2a) and an increase in pH of the solution (results nor shown), as observed previously 
for 13-93 glass and other bioactive glasses [33]. The weight loss and pH curves of the four 
groups of scaffolds showed trends similar to those observed in previous studies [33]. A 
more rapid increase at earlier times (up to ~7 days was followed by a slower increase 
thereafter and to a nearly constant value at longer times (longer than ~14 days). The Cu 
dopant concentrations used in the present study had no measurable effect on the weight 
loss of the 13-93 scaffolds. In addition, CuO dopant concentrations of 0.4 and 0.8 wt. % in 
the glass had no significant effect on the pH of the medium but the scaffolds doped with 
2.0 wt. % CuO produced an increase in the pH. When the reaction was terminated at 28 
days, the final weight loss and pH were 5.5 ± 0.5% and 7.80 ± 0.08, respectively, which 
are consistent with previous results for the conversion of 13-93 glass in an aqueous 
phosphate solution [33, 35].  
54 
 
Figure 2b shows that the release of Cu ions from the glass into SBF was faster at 
earlier immersion times and it decreased continuously with time. At any immersion time, 
the cumulative amount of Cu ions released into the medium increased with increasing CuO 
in as-fabricated glass. When the experiments were terminated at 28 days, the total amount 
of Cu ions released was 2.3, 4.6, and 13.8 ppm, respectively, for the scaffolds doped with 
0.4. 0.8 and 2.0 wt. % CuO. 
 
3.3 Assessment of MC3T3-E1 cell proliferation and ALP activity in vitro 
Quantitative measurement of MC3T3-E1 cell proliferation on the bioactive glass 
scaffolds showed a significant increase in cell number with incubation time for all four 
groups of scaffolds (Fig. 3). At each incubation time, the number of cells on the scaffolds 
doped with 0.4 and 0.8 wt. % CuO was not significant different from the undoped scaffolds. 
In comparison, the cell number for the scaffolds doped with 2.0 wt. % CuO was 
significantly lower than the undoped 13-93 scaffolds, showing that the scaffolds doped 
with 2.0 wt. % CuO had a lower ability to support the proliferation of MC3T3-E1 cells. 
The results of live cell/dead cell assays for MC3T3-E1 cells cultured on the four 
groups of scaffolds are shown in Fig. 4. The fluorochrome labeling of the cells cultured for 
up to 21 days on the 13-93 scaffolds and the 13-93 scaffolds doped with 0.4 or 0.8 wt. % 
CuO showed very few dead cells. The cells visible in the micrographs of these three groups 
were elongated and appeared to align along the long axis of the dense glass struts of the 
scaffold. The cells were well spread at all four culture intervals with numerous cytoplastic 
projections and they appeared to be well attached to the surface of the glass. In comparison, 
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fewer live cells and a larger number of dead cells were found in the images for the 13-93 
scaffolds doped with 2.0 wt. % CuO.  
SEM images in Fig. 5 show the morphology of MC3T3-E1 cells incubated on the 
surface of the four groups of scaffolds for 2, 7, and 14 days. The cells appeared to adhere 
to the surface of the scaffolds, presenting a well-spread morphology and maintaining their 
phenotype. The number of cells on the scaffolds increased with culture time. After an 
incubation time of 7 days, almost the whole surface of the scaffolds was covered with cells 
and cell spreading on the glass filaments was visible. The cells began to aggregate and the 
neighboring cells appeared to maintain physical contact with each other by multiple 
extensions. The cells incubated on the 13-93 scaffold and the 13-93 scaffold doped with 
0.4 and 0.8 wt. % CuO grew into the pores of scaffolds and showed the formation of 
numerous cell projections, features that indicated firm cell attachment to the surface. While 
the cells grew on the surface of the 13-93 scaffolds doped with 2.0 wt. % CuO, they showed 
little tendency to infiltrate into the pores. In general, the results of the live cell/dead cell 
assays and the SEM images of the cell morphology were consistent with the results of the 
CCK-8 cell proliferation assays. 
The results of spectrophotometric measurements of the ALP activity of MC3T3-E1 
cells cultured on the four groups of scaffolds for 3, 7, and 14 days are presented in Fig. 6. 
The ALP activity increased significantly with incubation time for the cells cultured on the 
13-93 scaffolds and the 13-93 scaffolds doped with 0.4 and 0.8 wt. % CuO, indicating that 
the cells were able to carry out an osteogenic function on these three groups of scaffolds. 
The significantly lower and almost constant ALP activity of the cells on the 13-93 scaffolds 
doped with 2.0 wt. % CuO indicated poor cytocompatibility for this scaffold group.  
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3.4 Assessment of new bone formation in rat calvarial defects in vivo 
Transmitted light images of H&E stained sections of the rat calvarial defects 
implanted for 6 weeks with the four groups of scaffolds, as fabricated (without BMP2) or 
loaded with BMP2 (1 µg/defect), are shown in Fig. 7. For the as-fabricated scaffolds 
composed of 13-93 glass and 13-93 glass doped with 0.4 and 0.8 wt. % CuO, new bone 
infiltrated into the edges (periphery) adjacent to the host bone, indicating good integration 
of the scaffolds with the surrounding calvarial bone, and also formed islands within the 
pores of the scaffolds (Fig. 7a1c1). Loading those three groups of scaffolds with BMP2 
enhanced their capacity to regenerate bone considerably, with new bone almost completely 
infiltrating the pores of the scaffold and bridging the edges of the defect (Fig. 7a2c2). In 
comparison, little new bone infiltrated the as-fabricated scaffolds composed of 13-93 glass 
doped with 2.0 wt. % CuO (Fig. 7d1). Loading those scaffolds with BMP2 improved their 
capacity to regenerate bone (Fig. 7d2). While new bone infiltrated the edges of the scaffold 
and also formed islands within the pores of the scaffold, the amount of new bone appeared 
to be significantly lower when compared to the other three groups of scaffolds.  
Since all the scaffolds had the same microstructure, their capacity to regenerate 
bone in the defects was compared by normalizing the amount of new bone to the total pore 
space (area) of the scaffolds (Fig. 8). The amount of new bone in the defects implanted 
with the as-fabricated 13-93 bioactive glass scaffolds was 46  8%, a value that was 
comparable to those in previous studies [30, 36]. Doping the 13-93 glass with 0.4 or 0.8 
wt. % CuO had no measurable effect on the capacity of the scaffolds to regenerate bone. 
The amount of new bone in the scaffolds doped with 0.4 wt. % CuO (49 ± 11%) and 0.8 
wt. % CuO (43 ± 9%) was not significantly different from the 13-93 scaffolds. Loading 
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those three groups of scaffolds with BMP2 significantly enhanced their ability to 
regenerate bone. The enhancement found for the undoped 13-93 scaffolds was comparable 
to the results of a previous study [30]. In comparison, doping the 13-93 scaffolds with 2.0 
wt. % CuO was significantly inhibited their capacity to regenerate bone (new bone = 0.8 ± 
0.7%). While the addition of BMP2 also improved the capacity of this scaffold group to 
regenerate bone, the amount of new bone was still significantly lower than the undoped 
13-93 scaffolds without BMP2. These results indicate a significant capacity of the scaffolds 
doped with 2.0 wt. % CuO to inhibit bone regeneration and the ability of BMP2 to stimulate 
robust bone regeneration in all four groups of scaffolds. 
 
3.5 Assessment of mineralized tissue and bioactive glass conversion 
 Transmitted light images of von Kossa stained sections of the rat calvarial defects 
implanted for 6 weeks with the four groups of bioactive glass scaffolds, as-fabricated or 
loaded with BMP2,  are shown in Fig. 9. The von Kossa staining detects a combination of 
bone and glass converted to HA (or phosphate material). The total von Kossa-positive area, 
39 ± 6%, 41 ± 7% and 40 ± 9%, respectively, for the defects implanted with the 13-93 
scaffolds, 13-93 scaffolds doped with 0.4 wt. % CuO and 13-93 scaffolds doped with 0.8 
wt. % CuO, showed no significant effect of the Cu doping (Fig. 10a). However, the total 
von Kossa-positive area for the defects implanted with the 13-93 scaffolds doped with 2.0 
wt. % CuO (18 ± 5%) was significantly lower. Loading the scaffolds with BMP2 
significantly enhanced the total von Kossa-positive area for all four groups of scaffolds. 
The von Kossa-positive area due to the glass conversion to HA showed no significant 
dependence on the amount of Cu doping used in this study (Fig. 10b).  The results showed 
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an increase for all four groups of scaffolds loaded with BMP2 but the increase was not 
significant. 
 
3.6 Assessment of fibrous tissue and marrow-like tissue 
In addition to new bone infiltration, scaffolds implanted in the rat calvarial defects 
were infiltrated with fibrous (soft) tissue and marrow-like tissue. The results of the 
assessment of bone marrow-like and fibrous tissue in the four groups of scaffolds, as-
fabricated or loaded with BMP2, are shown in Fig. 11. For the as-fabricated scaffolds, the 
pore space that was not infiltrated with new bone was filled mainly with fibrous tissue. In 
comparison, loading scaffolds with BMP2 reduced the amount of fibrous tissue but 
increased with amount of marrow-like tissue. The changes in fibrous and marrow-like 
tissue in all four groups of scaffolds due to the BMP2 loading were significant. In general, 
the results in Fig. 11 show that when combined with BMP2 loading, doping the 13-93 
scaffolds with increasing amount of Cu produced a decrease in marrow-like tissue and an 
increase in fibrous tissue. 
 
3.7 Assessment of angiogenesis 
Transmitted light images of PAS stained sections showed that blood vessels 
infiltrated the defects implanted with all four groups of scaffolds. As described earlier, in 
addition to the infiltration of new bone, the defects implanted with the as-fabricated 
scaffolds were also infiltrated with a considerable amount of fibrous tissue whereas the 
defects implanted with the BMP2-loaded scaffolds also contained a considerable amount 
of marrow-like tissue. Blood vessels were observed in the fibrous tissue while a 
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considerable amount of blood vessels was observed in the marrow-like tissue. Because the 
scaffolds doped with 2.0 wt. % CuO were infiltrated almost totally with fibrous tissue, the 
blood vessel area was evaluated separately in the fibrous tissue and in the new bone.  
Figure 12 shows images of PAS stained sections of the defects implanted with the 
four groups of scaffolds at 6 weeks post-implantation. Sparse capillary vessels were 
observed in the fibrous tissue within the as-fabricated 13-93 scaffolds but a larger number 
of capillaries were found in the Cu-doped 13-93 scaffolds, particularly the scaffolds doped 
with 2.0 wt. % CuO. The percent blood vessel area in the defects implanted with the four 
groups of scaffolds, determined as a fraction of the total amount of fibrous tissue that 
infiltrated the scaffolds (Fig. 13), showed an increase in the average blood vessel area with 
increasing CuO in the glass. The scaffolds doped with 2.0 wt. % CuO had the highest blood 
vessel area within the fibrous tissue (8 ± 1%) which was significantly higher than the values 
for the as-fabricated 13-93 scaffolds (4 ± 1%), the scaffolds doped with 0.4 wt. % CuO (5 
± 1%) and the scaffolds doped with 0.8 wt. % CuO (6 ± 1%). 
4. Discussion 
Angiogenesis is essential for the healing of bone defects, particularly large (critical-
size) defects. As the vasculature transports oxygen and nutrients to maintain healthy bone 
growth, the enhancement of angiogenesis should increase osteogenesis. Copper ions have 
been shown to play a direct role in stimulating angiogenesis [22, 23] and the delivery of 
Cu ions by borate-based bioactive glass scaffolds has been shown to enhance angiogenesis 
in subcutaneous sites and full thickness skin wounds in rodents [24, 25] and both 
angiogenesis and osteogenesis in rat calvarial defects [26]. In the present study, doping 
silicate 13-93 bioactive glass scaffolds with 0.4 and 0.8 wt. % CuO did not have a 
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significant effect on the response of MC3T3-E1 cells in vitro and on angiogenesis and 
osteogenesis in rat calvarial defects at 6 weeks postimplantation. In comparison, a dopant 
concentration of 2.0 wt. % CuO significantly enhanced angiogenesis in the fibrous tissue 
that infiltrated the scaffolds and significantly reduced osteogenesis. The addition of BMP2 
(1 µg/defect) to the undoped or Cu-doped scaffolds significantly improved their ability to 
stimulate osteogenesis in vivo.  
 
4.1 Release of Cu ions from scaffolds into SBF in vitro 
Doping the parent 13-93 glass with 0.4–2.0 wt. % CuO did not have a significant 
effect on the degradation and conversion of the scaffolds to HA in SBF, as measured by 
the weight loss of the scaffolds. Cu ions generally function as a network modifier in the 
glass whereas the conversion reaction of the glass is dependent mainly on the chemical 
degradation of the glass network itself. As the glass degraded and converted to HA, Cu 
ions were released into the SBF. Consequently, the release profile of the Cu ions as a 
function of time showed a trend that was approximately similar to the weight loss of the 
scaffolds (Fig. 1). Whereas the release profile is dependent on the degradation and 
conversion rate of the glass, the amount of Cu ions released from the glass at any time 
scaled as the amount of CuO originally incorporated into the as-fabricated glass.  
Theoretically, if all the Cu ions in glass dissolved into the medium, the 
concentration of Cu ions in the SBF would be 32, 64 and 160 ppm, respectively, for the 
scaffolds doped with 0.4, 0.8 and 2.0 wt. % CuO. The measured amount of Cu ions in the 
SBF when the experiments were terminated at 28 days was only 2.3, 4.6 and 13.8 ppm, 
respectively, for those three groups of scaffolds. The difference between the measured and 
61 
 
theoretical values could be accounted for in of the limited conversion of the 13-93 glass. 
Experimentally, the total weight loss of the three groups of scaffolds was 5.5 ± 0.5 wt. %. 
Assuming that the glass reacted completely and all the CaO in the glass reacted with 
phosphate ions from the medium to form HA, the theoretical weight loss would be 64%. If 
the Cu ions were released only from the fraction of the glass that reacted and converted to 
HA, the amount of Cu ions in the SBF is predicted to be 2.8, 5.5 and 13.7 ppm, respectively 
for the scaffolds doped with 0.4, 0.8 and 2.0 wt. % CuO. As these values are in good 
agreement with the measured values, the results indicate that Cu ions are released into the 
SBF almost exclusively from the reacted region of the glass.  
 
4.2 Effect of Cu-doped scaffolds on MC3T3-E1 cell proliferation and function in vitro 
The results of the present study showed that scaffolds of the parent (undoped) 13-
93 glass supported the proliferation and ALP activity of preosteoblastic MC3T3-E1 cells 
in vitro, which is compatible with the results of previous studies using 13-93 glass in the 
form of porous or fibrous scaffolds and osteoblastic cells [34, 37]. Doping the 13-93 glass 
with 0.4 and 0.8 wt. % CuO did not change the ability of the scaffolds to support MC3T3-
E1 cell proliferation on the surface and into the pores of the scaffolds (Fig. 3, 5). The ALP 
activity of the cells incubated for 7 and 14 days on the scaffolds doped with 0.4 and 0.8 
wt. % CuO was higher than the cells cultured on the parent 13-93 scaffolds, indicating that 
the Cu ions could stimulate the ability of the cells to carry out an osteogenic function.   
Doping the glass with 2.0 wt. % CuO significantly lowered the ability of the 
scaffolds to support the proliferation and ALP activity of the MC3T3-E1 cells. Live-
cell/dead cell assays showed that the scaffolds doped with 2.0 wt. % CuO were toxic to the 
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cells (Fig. 4).  The amount of Cu ions released from those scaffolds into the medium at day 
1 was sufficient to cause a significant reduction in the number of MC3T3-E1 cells on those 
scaffolds. Thereafter, as the Cu ion release rate decreased with time, the cell number 
increased but it was still significantly lower than the undoped 13-93 scaffolds at each 
incubation time. 
In the present study, the degradation of the scaffolds and release of ions were 
measured in SBF (1 g scaffold per 100 ml SBF) whereas the medium used in the cell culture 
experiments was α-MEM (1 scaffold of mass 50 mg in 2 ml medium). A previous study 
showed approximately the same degradation rate of 13-93 glass in SBF and in Dulbecco’s 
modified Eagle’s medium (DMEM) for the same mass to volume ratio of glass to 
immersion medium [38]. Consequently, it can be assume that for the same mass to volume 
ratio, the Cu ion release into α-MEM was approximately the same as in SBF. At day 1, the 
amount of Cu ions released from the scaffolds doped with 2.0 wt. % CuO into SBF was 3 
ppm. When compensated for the different mass to volume ratio, the amount of Cu ions 
released into the cell culture medium was 7 ppm and 10 ppm, respectively, at day 1 and 
day 2. Since the medium was replaced by fresh medium every 2 days, the concentration of 
Cu ions in the medium was highest and lowest, respectively, at the end of a two-day interval 
and at the beginning of the subsequent two-day interval. Furthermore, because the 
degradation rate of the glass decreased with time, the amount of Cu ions released into the 
medium during each successive two-day interval decreased with an increase in the total 
incubation time.     
A previous study showed that scaffolds of a borate-based bioactive glass (porosity 
= 85%) doped with up to 3.0 wt. % CuO, with a much faster degradation rate than the 13-
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93 glass used in the present study and, thus, a much faster Cu ion release rate, were not 
toxic to human bone marrow-derived stem cells (hBMSCs) in vitro [26]. The proliferation 
and ALP activity of hBMSCs incubated in the ionic dissolution product of silicate-based 
mesoporous bioactive glass that contained up to 5% Cu (molar fraction) did not show a 
significant dependence on the Cu content of the glass [39]. Mouse L929 fibroblasts, when 
incubated in the ionic dissolution product of Cu-containing intra-uterine devices, showed 
a decreasing viability with increasing Cu ion concentration in the range 0100 ppm, 
reaching 50% viability and zero viability, respectively, when exposed to 46 ppm and 100 
ppm for 24 h [40].    
Metals such as Ni, Co, Ag, Cu and Pd are common components of orthopedic and 
dental implants and the effects of their metal ion toxicity to cells in vitro have been widely 
studied. It is well established that above some threshold concentration, those metal ions are 
toxic to cells and that the threshold concentrations depends on both the composition of the 
metal and the cell line [41, 42]. Copper ions have been reported to catalyze the interaction 
between superoxide and hydrogen peroxide by the Haber-Weiss reaction, resulting in the 
reduction of Cu2+ to Cu+ and the formation of toxic hydroxyl radicals [43]. Consequently, 
above a certain concentration, Cu ions can be toxic to cells due to the formation of an 
abundance of hydroxyl radicals.  
In the present study, the toxicity of the scaffolds doped with 2.0 wt. % CuO 
appeared to result from a lower average Cu ion concentration in the medium when 
compared to the studies mentioned above. The difference may reside in a variety of factors. 
As described above, the threshold metal ion concentration for toxicity is known to depend 
on the cell line [42]. Another factor is the concentration gradient of the Cu ions in the 
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medium. Cells cultured in medium containing dissolved Cu ions experience a more 
uniform concentration of ions. In comparison, there is a gradient in Cu ion concentration 
when cells are incubated on the surface of a Cu-releasing bioactive glass scaffold, as done 
in the present study. The Cu ion concentration at the surface of the scaffold is typically 
much higher than the average concentration of the medium. In the present study, although 
the average Cu ion concentration in the medium was 7 and 10 ppm, respectively, at days 
1 and 2, the concentration was expected to be considerably higher at the surface of the 
scaffolds in contact with the cells and within the pores of the scaffolds. The composition 
of the glass scaffold can also have an effect on the threshold Cu ion concentration for 
toxicity because other ions such as Ca, Na, K, B and Si can be released (depending on the 
glass composition) and there is typically an increase in pH of the medium.    
 
4.3 Effect of Cu-doped scaffolds on bone regeneration and angiogenesis in vivo 
Bone regeneration at 6 weeks in rat calvarial defects implanted with the four groups 
of scaffolds showed trends similar to the MC3T3-E1 cell proliferation results described 
above. Doping the parent 13-93 glass with 0.4 and 0.8 wt. % CuO did not affect the capacity 
of the scaffolds to regenerate bone (Fig. 8). In comparison, bone regeneration in the defects 
implanted with the scaffolds doped with 2.0 wt. % was significantly inhibited and the 
amount of new bone was almost negligible (0.8 ± 0.7% of the available pore volume). The 
lack of ability to support new bone infiltration by these scaffolds is presumably related to 
a high concentration of Cu ions at the surface (periphery) of the scaffolds and within the 
pores of the scaffolds (discussed above) which was presumably toxic to osteoblastic cells 
in vitro.   
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As bone regeneration in the defects implanted with scaffolds of 13-93 glass doped 
with 2.0 wt. % CuO was very limited, the formation of blood vessels was evaluated 
separately in the new bone and in the fibrous tissue that infiltrated the pores of the scaffolds 
[Fig. 13]. The blood vessel area in the new bone was not affected by doping the parent 13-
93 glass with 0.4 and 0.8 wt. % CuO. In comparison, the blood vessel area in the fibrous 
tissue increased with increasing CuO in the glass. The blood vessel area in the fibrous tissue 
that infiltrated the scaffolds doped with 2.0 wt. % CuO was significantly higher than the 
parent 13-93 scaffolds, with a value that was approximately twice that for the parent 13-93 
scaffolds.  
The significant increase in blood vessel area in the soft tissue that infiltrated the 
scaffolds doped with 2.0 wt. % CuO is compatible with the observations of previous studies 
which showed the capacity of Cu ion release from borate-based bioactive glass and calcium 
phosphate-based scaffolds to enhance angiogenesis in animal models of soft tissue repair. 
Fibrous scaffolds of a borate bioactive glass doped with 0.1–2.0 wt. % CuO were found to 
be biocompatible while the scaffolds doped with 0.4 wt. % CuO significantly enhanced 
blood vessel formation in rat subcutaneous sites at 6 weeks post-implantation [44]. Copper 
ion release from calcium phosphate-based scaffolds was found to enhance angiogenesis in 
the peritoneal cavity of mice [21].  
The effect of Cu ion release from borate-based bioactive glass scaffolds on bone 
regeneration and angiogenesis in osseous defects has been investigated in a rodent model. 
The borate-based bioactive glass had a much faster degradation and conversion rate to HA. 
In one study, borate bioactive glass doped with 0.4 wt. % CuO were formed into different 
porous architectures, referred to as trabecular, oriented and fibrous, and implanted for 12 
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weeks in rat calvarial defects. The Cu doping had no significant effect on bone regeneration 
and blood vessel area in the defects implanted with the trabecular and oriented scaffolds 
but it enhanced bone regeneration by the fibrous scaffolds [45]. A recent study found that 
a borate-based bioactive glass doped with 3.0 wt. % CuO enhanced both blood vessel 
formation and bone regeneration in rat calvarial defects at 8 weeks postimplantation [26].  
While important, angiogenesis is a transitory event in bone regeneration, typically 
more prominent at an earlier stage of defect healing. Presumably the angiogenesis event 
had considerably diminished by the six-week implantation time used in the present study. 
However, doping the 13-93 glass with 0.4 and 0.8 wt. % CuO had no significant effect on 
bone regeneration at 6 weeks postimplantation.  
 Loading scaffolds composed of the parent 13-93 glass with BMP2 (1 µg/defect), 
significantly enhanced bone regeneration in the rat calvarial defects at 6 weeks 
postimplantation (Fig. 8), in agreement with the results of recent studies [30, 36]. Loading 
the 13-93 scaffolds doped with 0.4 and 0.8 wt. % CuO also enhanced bone regeneration 
significantly but the enhancement was comparable to the 13-93 scaffolds. The combination 
of BMP2 loading and Cu doping produced no significant benefit over the BMP2 loading 
alone, indicating no synergistic effects between the BMP2 loading and the Cu doping at 
the concentrations used in the present study. Although there are concerns about the safety 
of supra-physiological doses of BMP2 in vivo, loading silicate-based bioactive glass 
scaffolds with clinically safe doses of BMP2 appears to considerably more effective than 






Scaffolds with a grid-like microstructure composed of silicate 13-93 bioactive glass 
doped with varying amounts of Cu (0-2.0 wt. % CuO) were created by robotic deposition 
and evaluated in vitro and in vivo. When immersed in simulated body fluid (SBF), the 
scaffolds released Cu ions in a dose-dependent manner but the Cu doping had no significant 
effect on the degradation and conversion of the scaffolds to hydroxyapatite. CuO dopant 
concentrations of 0.4 and 0.8 wt. % had no significant effect on the number and alkaline 
phosphatase activity of MC3T3-E1 cells cultured on the scaffolds in vitro and on bone 
regeneration and angiogenesis in rat calvarial defects at 6 weeks postimplantation. CuO 
dopant concentration of 2.0 wt. % significantly reduced the number and ALP activity of 
MC3T3-E1 cells in vitro and bone regeneration in vivo but significantly enhanced blood 
vessel area in the fibrous tissue that infiltrated the scaffolds. Loading the undoped or Cu-
doped scaffolds with BMP2 (1 µg/defect) significantly enhanced their capacity to 
regenerate bone. Doping 13-93 bioactive glass scaffolds with 0.4 and 0.8 wt. % CuO had 
no significant effect on the response of MC3T3-E1 cells in vitro and bone regeneration in 
rat calvarial defects in vivo but a CuO concentration of 2.0 wt. % was toxic to the MC3T3-
E1 cells and severely inhibited bone regeneration.  
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Fig. 1. (a) Optical image of the four groups of as-fabricated scaffolds prepared by 
robocasting, composed of (left to right) 13-93 glass and 13-93 glass doped with 0.4, 0.8 
and 2.0 wt. % CuO; (b) SEM image of the top surface of a 13-93 scaffold doped with 0.8 
wt. % CuO; (c) SEM image of the surface of a glass filament (0.8 wt. % CuO) after 






Fig. 2. (a) Weight loss of 13-93 scaffolds and scaffolds doped with 0.4, 0.8 and 2.0 wt. % 
CuO and (b) cumulative amount of Cu ions released from 13-93 scaffolds doped with 0.4, 






Fig. 3. Cell proliferation, as measured by CCK-8 assay, of MC3T3-E1 cells cultured on 
the four groups of bioactive glass scaffolds for the times shown. (Average ± SD, n = 3; 
*significant difference when compared to 13-93 scaffold at the same incubation time; 








Fig. 4. Fluorescent images of MC3T3-E1cells incubated for 2, 7, 14 and 21 days on the 
four groups of bioactive glass scaffolds. Double staining was used to detect live cells as 





Fig. 5. SEM images of the four groups of bioactive glass scaffolds seeded with MC3T3-
E1 cells and incubated for 2, 7 and 14 days. (C1: cells on surface filaments; C2: cells on 






Fig. 6. Alkaline phosphatase (ALP) activity of MC3T3-E1 cells cultured on 13-93 
scaffolds and on 13-93 scaffolds doped with 0.4, 0.8 and 2.0 wt. % CuO for the times 
shown. Enzyme activity is expressed as ng of pNP formed per µg dsDNA per 30 min. 
(Average ± SD, n = 3; *significant difference when compared to 13-93 scaffold at the same 
incubation time; #significant difference when compared to same group at different 





Fig. 7. Transmitted light images of H&E-stained sections of rat calvarial defects implanted 
with the four groups of bioactive glass scaffolds, as fabricated (left) or loaded with BMP2 
(right), at 6 weeks postimplantation. N = new bone; O = host bone; * = bony island; G = 






Fig. 8. Percent new bone in rat calvarial defects implanted with the four groups of scaffolds, 
13-93 and 13-93 doped with 0.4, 0.8 and 2.0 wt. % CuO, as-fabricated or loaded with 
BMP2, at 6 weeks postimplantation. The amount of new bone is shown as a percent of the 
available pore space (area) of the scaffolds. (*significant difference between groups; 





Fig. 9. Transmitted light images of von Kossa stained sections of rat calvarial defects 
implanted with the four groups of scaffolds, as-fabricated (left) or loaded with BMP2 
(right), at 6 weeks postimplantation. N = new bone; O = host bone; G = bioactive glass; 





Fig. 10. Percent total von Kossa positive (vK+) area (a) and vK+ area due to the bioactive 
glass conversion (b), determined as a fraction of the total defect area, for rat calvarial 
defects implanted with the four groups of scaffolds, as fabricated or loaded with BMP2, at 
6 weeks post-implantation. (average ± SD; *significant difference between groups; 





Fig. 11. Percent bone marrow-like tissue (a) and fibrous tissue (b) in rat calvarial defects 
implanted with the four groups of scaffolds, as fabricated or loaded with BMP2, at 6 weeks 
post-implantation (*significant difference between groups; #significant difference when 





Fig. 12. (Left): Transmitted light images of PAS stained sections of rat calvarial defects 
implanted with the four groups of scaffolds (without BMP2) at 6 weeks postimplantation; 
(Right): magnified images of the boxed areas in the corresponding images on the left. (N 





Fig. 13. Percent blood vessel area in rat calvarial defects implanted with the four groups of 
scaffolds at 6 weeks postimplantation. The blood vessel area in the fibrous tissue and in 
the new bone are shown (as a percentage of the total fibrous tissue and total new bone, 
respectively). (*significant difference between groups; #significant difference when 






Fig. S1. Raman spectra of the un-doped 13-93 scaffold and the 13-93 bioactive glass 
scaffolds doped with 0.4 wt.% CuO, 0.8 wt.% CuO and 2 wt.% CuO after immersion in 
SBF for 28 days. For comparison, the pattern of a reference hydroxyapatite (A027249-1) 






Bone regeneration in rat calvarial defects implanted with strong porous bioactive 
glass (13-93) scaffolds was studied at implantation times of 12 and 24 weeks and compared 
with a similar study at 6 weeks. Bone regeneration in the defects implanted with the as-
fabricated scaffolds increased significantly with increase in the implantation time from 6 
to 24 weeks. Pretreating the scaffolds to convert a thin surface layer to hydroxyapatite 
enhanced bone regeneration at 6 weeks but not at 12 or 24 weeks. Scaffolds loaded with 
BMP2 (1 µg/defect) significantly enhanced bone regeneration at all three implantation 
times. The pore space of the BMP2-loaded scaffolds was almost completely infiltrated with 
lamellar bone within 12 weeks. The pretreatment or BMP2 loading did not affect the 
amount of bioactive glass converted to hydroxyapatite at 24 weeks (30%). While blood 
vessels were present in the new bone that infiltrated all three groups of scaffolds, the 
BMP2-loaded scaffolds had a significantly higher number of blood vessels and blood 
vessel area at 6 and 12 weeks post-implantation. Strong porous bioactive glass (13-93) 
scaffolds loaded with clinically acceptable levels of BMP2 could provide promising 
implants for healing structural (loaded) bone defects within a clinically relevant time. 
Scaffolds with a grid-like microstructure composed of silicate 13-93 bioactive glass 
doped with varying amounts of Cu (0-2.0 wt. % CuO) were created by robotic deposition 
and evaluated in vitro and in vivo. When immersed in simulated body fluid (SBF), the 
scaffolds released Cu ions in a dose-dependent manner but the Cu doping had no significant 
effect on the degradation and conversion of the scaffolds to hydroxyapatite. CuO dopant 
concentrations of 0.4 and 0.8 wt. % had no significant effect on the number and alkaline 
phosphatase activity of MC3T3-E1 cells cultured on the scaffolds in vitro and on bone 
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regeneration and angiogenesis in rat calvarial defects at 6 weeks postimplantation. CuO 
dopant concentration of 2.0 wt. % significantly reduced the number and ALP activity of 
MC3T3-E1 cells in vitro and bone regeneration in vivo but significantly enhanced blood 
vessel area in the fibrous tissue that infiltrated the scaffolds. Loading the undoped or Cu-
doped scaffolds with BMP2 (1 µg/defect) significantly enhanced their capacity to 
regenerate bone. Doping 13-93 bioactive glass scaffolds with 0.4 and 0.8 wt. % CuO had 
no significant effect on the response of MC3T3-E1 cells in vitro and bone regeneration in 
rat calvarial defects in vivo but a CuO concentration of 2.0 wt. % was toxic to the MC3T3-
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